Lipophilic prodrugs of Hsp90 inhibitor geldanamycin for nanoencapsulation in poly(ethylene glycol)-b-poly(ε-caprolactone) micelles

被引:49
作者
Forrest, M. Laird
Zhao, Anni
Won, Chee-Youb
Malick, A. Waseem
Kwon, Glen S.
机构
[1] Univ Wisconsin, Div Pharmaceut Sci, Sch Pharm, Madison, WI 53705 USA
[2] Hoffmann La Roche Inc, Div Pharmaceut Sci, Sch Pharm, Nutley, NJ 07110 USA
关键词
geldanamycin; Hsp90; nanocarrier; poly(ethylene glycol)-b-poly(epsilon-caprolactone); polymer micelle;
D O I
10.1016/j.jconrel.2006.07.003
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
A solvent and Cremephor (R) free, formulation of the anticancer chemotherapeutic geldanamycin was prepared using amphiphilic block copolymer micelles of poly(ethylene glycol)-b-poly(epsilon-caprolactone) (PEG-b-PCL). Although geldanamycin was not solubilized by PEG-b-PCL micelles, fatty acid prodrugs of geldanamycin were encapsulated in PEG-b-PCL micelles by a co-solvent extraction technique. Resulting PEG-b-PCL micelles were < 120 nm in diameter and solubilized > 20% w/w geldanamycin prodrugs increasing aqueous solubility to > 2 mg/mL. PEG-b-PCL micelles released the geldanamycin prodrugs over several days, t(1/2) 2.2 to 9.6 days. The free prodrugs hydrolyzed rapidly, t(1/2) < 6 h, into the geldanamycin analogue 17-beta-hydroxyethylamino-17-demethoxygeldanamycin, which has high activity against MCF-7 breast cancer cells, IC50 240 nM. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:139 / 149
页数:11
相关论文
共 51 条
[1]   Hydrolyzable hydrophobic taxanes: synthesis and anti-cancer activities [J].
Ali, S ;
Ahmad, I ;
Peters, A ;
Masters, G ;
Minchey, S ;
Janoff, A ;
Mayhew, E .
ANTI-CANCER DRUGS, 2001, 12 (02) :117-128
[2]   Micelles of methoxy poly(ethylene oxide)-b-poly(ε-caprolactone) as vehicles for the solubilization and controlled delivery of Cyclosporine A [J].
Aliabadi, HM ;
Mahmud, A ;
Sharifabadi, AD ;
Lavasanifar, A .
JOURNAL OF CONTROLLED RELEASE, 2005, 104 (02) :301-311
[3]   Polycaprolactone-b-poly(ethylene oxide) copolymer micelles as a delivery vehicle for dihydrotestosterone [J].
Allen, C ;
Han, JN ;
Yu, YS ;
Maysinger, D ;
Eisenberg, A .
JOURNAL OF CONTROLLED RELEASE, 2000, 63 (03) :275-286
[4]   Phase I pharmacokinetic and pharmacodynarnic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies [J].
Banerji, U ;
O'Donnell, A ;
Scurr, M ;
Pacey, S ;
Stapleton, S ;
Asad, Y ;
Simmons, L ;
Maloney, A ;
Raynaud, F ;
Campbell, M ;
Walton, M ;
Lakhani, S ;
Kaye, S ;
Workman, P ;
Judson, I .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (18) :4152-4161
[5]   Geldanamycin-associated inhibition of intracellular trafficking is attributed to a co-purified activity [J].
Barzilay, E ;
Ben-Califa, N ;
Supino-Rosin, L ;
Kashman, Y ;
Hirschberg, K ;
Elazar, Z ;
Neumann, D .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (08) :6847-6852
[6]   Alkyl esters of camptothecin and 9-nitrocamptothecin: Synthesis, in vitro pharmacokinetics, toxicity, and antitumor activity [J].
Cao, ZS ;
Harris, N ;
Kozielski, A ;
Vardeman, D ;
Stehlin, JS ;
Giovanella, B .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (01) :31-37
[7]  
Citri A, 2004, CELL CYCLE, V3, P51
[8]   KINETIC MEDIUM EFFECTS .3. SOLVENT EFFECTS ON A1 AND A2 HYDROLYSES IN WATER-DIMETHYL SULPHOXIDE MIXTURES [J].
COX, BG ;
MCTIGUE, PT .
AUSTRALIAN JOURNAL OF CHEMISTRY, 1967, 20 (09) :1815-&
[9]   GELDANAMYCIN, A NEW ANTIBIOTIC [J].
DEBOER, C ;
MEULMAN, PA ;
WNUK, RJ ;
PETERSON, DH .
JOURNAL OF ANTIBIOTICS, 1970, 23 (09) :442-&
[10]   Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1 [J].
Egorin, MJ ;
Zuhowski, EG ;
Rosen, DM ;
Sentz, DL ;
Covey, JM ;
Eiseman, JL .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2001, 47 (04) :291-302